{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:33:54Z","timestamp":1789515234961,"version":"build-2803163510"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PS 148606"],"award-info":[{"award-number":["PS 148606"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 79327"],"award-info":[{"award-number":["MOP 79327"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02371","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T14:26:33Z","timestamp":1539699993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine"],"prefix":"10.3389","volume":"9","author":[{"given":"Nancy","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Vedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Y.","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"B1","unstructured":"Global tuberculosis report 20172017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nm0307-295","article-title":"From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis","volume":"13","author":"Dorman","year":"2007","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1172\/JCI34614","article-title":"Confronting the scientific obstacles to global control of tuberculosis","volume":"118","author":"Young","year":"2008","journal-title":"J Clin Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","article-title":"Protection by BCG vaccine against tuberculosis: a systemic review of randomized controlled trials","volume":"58","author":"Mangtani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrmicro1211","article-title":"The success and failure of BCG-implications for a novel tuberculosis vaccine","volume":"3","author":"Andersen","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.it.2014.04.006","article-title":"Tuberculosis vaccines\u2013rethinking the current paradigm","volume":"35","author":"Andersen","year":"2014","journal-title":"Trends Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2014.00152","article-title":"Recombinant BCG: innovations on an old vaccine. scope of BCG strains and strategies to improve long-lasting memory","volume":"5","author":"Costa","year":"2014","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ebiom.2016.04.010","article-title":"Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-na\u00efve adults: a randomized, active-controlled, first-in-human Phase 1 trial","volume":"7","author":"Hoft","year":"2016","journal-title":"EBioMedicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.vaccine.2012.02.036","article-title":"Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis","volume":"30","author":"Brennan","year":"2012","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1586\/14760584.2014.929947","article-title":"Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future?","volume":"13","author":"Smaill","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0141687","DOI":"10.1371\/journal.pone.0141687","article-title":"A phase I, open-label trial, evaluating the safety and immunogenicity of candidate tuberculosis vaccines AERAS-402 and MVA85A, administered by prime-boost regime in BCG-vaccinated healthy adults","volume":"10","author":"Sheehan","year":"2015","journal-title":"PLoS ONE"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/mt.2008.59","article-title":"Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine","volume":"16","author":"Roediger","year":"2008","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fcimb.2017.00034","article-title":"Vesicular stomatitis virus-vectored multi-antigen tuberculosis vaccine limits bacterial proliferation in mice following a single intranasal dose","volume":"7","author":"Zhang","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1098\/rstb.2011.0097","article-title":"Tuberculosis vaccines: beyond bacille Calmette\u2013Gu\u00e9rin","volume":"366","author":"McShane","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.vaccine.2009.10.114","article-title":"Non-clinical efficacy and safety of HyVac4:IC31vaccine administered in a BCG prime\u2013boost regimen","volume":"28","author":"Skeiky","year":"2010","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.vaccine.2017.01.055","article-title":"Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials","volume":"35","author":"Norrby","year":"2017","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.vaccine.2012.05.035","article-title":"Improved CD4? T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72\/AS01 as compared to the M72\/AS02 and Mtb72F\/AS02 tuberculosis candidate vaccine formulations: a randomized trial","volume":"31","author":"Leroux","year":"2013","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1128\/CVI.00133-10","article-title":"Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F\/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults","volume":"17","author":"Leroux","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1086\/314640","article-title":"Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis","volume":"179","author":"Ravan","year":"1999","journal-title":"J Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.4049\/jimmunol.1103556","article-title":"Dissecting mechanisms of immunodominance to the common tuberculosis antigens ESAT-6, CFP10, Rv2031c (hspX), Rv2654c (TB7","volume":"188","author":"Arlehamn","year":"2012","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/IAI.64.1.16-22.1996","article-title":"Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG","volume":"64","author":"Harboe","year":"1996","journal-title":"Infect Immun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1128\/IAI.68.2.791-795.2000","article-title":"ESAT-6 subunit vaccination against Mycobacterium tuberculosis","volume":"68","author":"Brandt","year":"2000","journal-title":"Infect Immun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1016\/j.vaccine.2004.11.051","article-title":"Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6","volume":"15","author":"Langermans","year":"2005","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.1016\/j.vaccine.2016.08.075","article-title":"Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: routes of immunization and TLR agonists critically impact vaccine's efficacy","volume":"34","author":"Gupta","year":"2016","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/intimm\/dxq033","article-title":"Immunomodulation by hepatitis C virus-derived proteins: targeting human dendritic cells by multiple mechanisms","volume":"22","author":"Krishnadas","year":"2010","journal-title":"Int Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0150606","DOI":"10.1371\/journal.pone.0150606","article-title":"A protocol for the comprehensive flow cytometric analysis of immune cells in normal and inflamed murine non-lymphoid tissues","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS ONE"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.4049\/jimmunol.1501996","article-title":"BCG re-vaccination of adults with latent Mycobacterium tuberculosis infection induces long-lived BCG-reactive natural killer cell responses","volume":"4","author":"Suliman","year":"2016","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"g4643","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.vaccine.2005.07.033","article-title":"Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis","volume":"24","author":"Griffin","year":"2006","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"730702","DOI":"10.1155\/2011\/730702","article-title":"Recombinant HBHA boosting effect on BCG induced immunity against Mycobacterium tuberculosis infection","volume":"2011","author":"Guerrero","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/infdis\/jis941","article-title":"Longitudinal changes in CD4+ T-cell memory responses induced by BCG vaccination of newborns","volume":"207","author":"Soares","year":"2013","journal-title":"J Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1084\/jem.20041852","article-title":"Repeated stimulation of CD4 e ector T cells can limit their protective function","volume":"201","author":"Jelley-Gibbs","year":"2005","journal-title":"J Exp Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.immuni.2013.07.003","article-title":"Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting","volume":"39","author":"Fraser","year":"2013","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.4049\/jimmunol.1201153","article-title":"Maintenance of peripheral T cell responses during Mycobacterium tuberculosis infection","volume":"189","author":"Reiley","year":"2012","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e94192","DOI":"10.1371\/journal.pone.0094192","article-title":"CD8+ regulatory T cells, and not CD4+ T cells, dominate suppressive phenotype and function after in vitro live BCG activation of human cells","volume":"9","author":"Boer","year":"2014","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1399-3038.2010.01051.x","article-title":"Neonatal BCG vaccination induces IL-10 production by CD4+ CD25+ T cells","volume":"21","author":"Akkoc","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.imbio.2010.09.003","article-title":"The immune responses of central and effector memory BCG-specific CD4+ T cells in BCG-vaccinated PPD+ donors were modulated by Treg cells","volume":"216","author":"Li","year":"2011","journal-title":"Immunobiology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.cytogfr.2010.10.004","article-title":"IL-17 and Th17 cells in tuberculosis","volume":"21","author":"Torrado","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.4049\/jimmunol.180.3.1962","article-title":"Distinct, specific IL-17 and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response","volume":"180","author":"Scriba","year":"2008","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00281-015-0490-8","article-title":"CD8 T cells and Mycobacterium tuberculosis infection","volume":"37","author":"Lin","year":"2015","journal-title":"Sem Immunopathol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.1016\/j.vaccine.2012.10.031","article-title":"The recombinant tuberculosis vaccine rBCG \u0394ureC::hly(+) induces apoptotic vesicles for improved priming of CD4+ and CD8+ T cells","volume":"30","author":"Farinacci","year":"2012","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nm906","article-title":"Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis","volume":"9","author":"Schaible","year":"2003","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in phase 1 open-label randomized clinical trial","volume":"18","author":"Grode","year":"2013","journal-title":"Vaccine"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1016\/j.vaccine.2009.05.048","article-title":"Novel recombinant BCG expressing perfringolysin O and the over expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mtb","volume":"27","author":"Sun","year":"2009","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/eji.201243286","article-title":"CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8+ CD39+ regulatory T cells","volume":"43","author":"Boer","year":"2013","journal-title":"Eur J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.bcp.2011.05.019","article-title":"CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?","volume":"82","author":"D'Acquisto","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.1000362","article-title":"Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain","volume":"184","author":"Cowley","year":"2010","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/ni1230","article-title":"CD4-CD8 lineage commitment: an inside view","volume":"6","author":"Kappes","year":"2005","journal-title":"Nat Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/icb.2010.84","article-title":"Interleukin-10 limits the expansion of immunoregulatory CD4-CD8- T cells in autoimmune-prone non-obese diabetic mice","volume":"88","author":"Hillhouse","year":"2010","journal-title":"Immunol Cell Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/mi.2015.91","article-title":"Double-negative T resident memory cells of the lung react to influenza virus infection via CD11c(hi) dendritic cells","volume":"9","author":"Neyt","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1164\/rccm.2204027","article-title":"CD8+ T cells in tuberculosis","volume":"166","author":"Lazarevic","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.4049\/jimmunol.1003292","article-title":"Highly activated cytotoxic CD8 T cells express protective IL-10 at the peak of Coronavirus-induced encephalitis","volume":"186","author":"Trandem","year":"2011","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.virol.2010.05.004","article-title":"IFN\u03b3-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment","volume":"404","author":"Palmer","year":"2010","journal-title":"Virology"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1099\/0022-1317-79-7-1751","article-title":"Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease","volume":"79","author":"Spender","year":"1998","journal-title":"J Gen Virol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nm.1929","article-title":"Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10","volume":"15","author":"Sun","year":"2009","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.cyto.2006.11.008","article-title":"Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal","volume":"36","author":"Tamang","year":"2006","journal-title":"Cytokine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T05:24:29Z","timestamp":1605245069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2018.02371"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02371","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"article-number":"2371"}}